MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc.

生物技术

Chicago，Illinois 5,918 位关注者

MAIA Biotechnology is a targeted therapy, immuno-oncology company focused on development of first-in-class drugs

关注

关于我们

MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A publicly traded company based in Chicago, MAIA (NYSE American: MAIA) is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into human clinical trials. MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.

网站
https://www.maiabiotech.com
所属行业
生物技术
规模
2-10 人
总部
Chicago，Illinois
类型
私人持股
创立
2018
领域
Drug development、Oncology、Research、Targeted Therapy、Immmuno-Oncology、Telomere Targeting、Biotechnology、Small Molecule、Pharmaceutical和Immunotherapy

地点

  • 主要

    444 West Lake Street

    Suite 1700

    US，Illinois，Chicago，60606

    获取路线

MAIA Biotechnology, Inc.员工

查看全部员工

动态

相似主页

查看职位

融资

MAIA Biotechnology, Inc. 共 9 轮

上一轮

上市后股权

US$1,000,000.00

在 Crunchbase 上查看更多信息